Division of Hematology and Oncology Archive — Page 1 of 5

Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)
August 3, 2023

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

By Leigh MacMillan
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

By Tom Wilemon
April 18, 2023

Vanderbilt mourns loss of former Hematology leader Krantz

Sanford Krantz, MD, internationally recognized authority on hematology and erythropoietin and professor of Medicine, Emeritus, died April 13 at his home. He was 89.

By Vanderbilt Health News
Jordan Berlin, MD, was recognized for his leadership serving on an NCI team that researched and recommended changes to clinical trial protocols that expanded the role of advanced practice providers.
April 6, 2023

National Cancer Institute honors Berlin’s contributions, leadership

Vanderbilt’s Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.

By Tom Wilemon
March 30, 2023

New treatment helps mitigate hair loss for chemotherapy patients

Vanderbilt-Ingram Cancer Center has started offering scalp cooling, which mitigates hair loss for patients receiving certain chemotherapy regimens.

By Tom Wilemon
Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan